Analysts Are Bullish on Heartflow (HTFL) Stock. Here’s Why
Heartflow Inc. (NASDAQ:HTFL) hit a new all-time high after reporting Q2 revenue growth of 48% to $64.08 million from $43.2 million. The company raised full-year revenue guidance to 40% to 42% growth, targeting $246 million to $250 million. Net loss widened to $15.7 million. Analysts at Stifel and JPMorgan raised price targets to $45.
How this was made
The 30-second read
Why it matters
Q2 revenue growth (48% YoY) and a raised full-year revenue outlook (40% to 42% growth, $246M to $250M) are the core catalysts, while the 70.6% wider net loss underscores continued cost pressure.
Market read
Traders get a fresh, numbers-based guidance raise and Q2 revenue beat for HTFL, plus sell-side target increases that can reinforce momentum.
What to watch
The article highlights revenue growth engines (FFR and Plaque) but provides no detail on operating expense trajectory or cash burn, which are critical for risk-adjusted upside.
Background
Heartflow is an AI technology company for diagnosing coronary artery disease, with revenue tied to its US Fractional Flow Reserve business and Plaque case volume.
Ticker impact
Heartflow (HTFL) reported Q2 revenue up 48% to $64.08M and raised full-year revenue growth to 40% to 42% ($246M to $250M).
Near-term bias remains upward while traders price in the higher revenue outlook; upside may be capped by the larger net loss.
The article discloses a concrete guidance raise and Q2 revenue beat, which are direct valuation drivers, while also noting net loss widened 70.6% to $15.7M, which can temper follow-through.
Market effects
Strength in an AI-enabled CAD diagnostic name may support sentiment for medical AI and cardiology diagnostics, though profitability remains a key debate.
Primarily US small/mid-cap growth sentiment, with limited direct regional spillover implied.
Limited global read-through beyond medical device/diagnostics investor appetite for AI platforms.
Counterpoint
The guidance raise may not translate into earnings power if losses keep widening, so the stock’s momentum could reverse on any margin or cost-control disappointment.
Key entities
- companyHeartflow Inc.
NASDAQ-listed AI diagnostics company for coronary artery disease; raised full-year revenue growth outlook after strong Q2 revenue.
- executiveJohn Farquhar
President and CEO quoted on category leadership, under-penetrated market, and improving gross margin/operating leverage.
- analyst_firmStifel
Raised price target to $45 and maintained buy rating citing Q2 revenue outperformance.
- analyst_firmJPMorgan
Raised price target to $45 and maintained overweight rating.
- analyst_firmWells Fargo
Upgraded price target to $39 from $37, citing potential for upside versus guidance.
